Series A third close · Biotech
mbiomics secures €12m in third Series A close
The financing brings the Series A to €30m and supports microbiome drug development.
mbiomics announced a €12 million third Series A close on April 28, 2026, taking the round to €30 million. Existing investors including MIG Fonds and Bayern Kapital participated.
The Munich company will strengthen preclinical data and manufacturing capabilities as it prepares MBX-116 for clinical evaluation. The live bacterial therapy is being developed alongside immune checkpoint inhibitors for advanced melanoma.
Use of funds
Strengthen IND-enabling pharmacological data
Accelerate GMP development and manufacturing
Prepare MBX-116 for clinical evaluation
Funding history
Series A third close · This round€12M
Series A first close€13M